Tod Woolf

FAQ About Tod Woolf

• What is Tod Woolf's address?

  Tod Woolf is located at
  Greater Boston, Greater Boston, United States

• What is Tod Woolf's job title?

  Tod Woolf is a
  Innovative developer of biomedical technologies. Experienced in Academic Technology Transfer, BD, IP management & translation of scientific platforms into products. Communication skills demonstrated by publications, presentations including keynote addresses and team building. Generated >300M in grant, alliance, licenses & equity revenues. Co-developed Therapeutic Editing(1995), MOD mRNA Therapeutics & Vax platform (1997), STEALTH RNAi(2003), Self-Delivering RNAi(2009). Co-founded Sequitur, acquired by Invitrogen and RXi (public, 2008), ETAGEN & participated in formation of more than twenty other startups. Served as CBO at X-Body (acquired by Juno). KEY PATENTS, PUBS & PRODUCTS 1) THERAPEUTIC RNA EDITING: Pursued by ETAGEN, ProQR, Beam & Korro Woolf, et al “Towards the therapeutic editing of mutated RNA sequences” PNAS, 1995 2) mRNA THERAPEUTICS and Vaccines: Early patent application on MOD mRNA for protein replacement & vaccines. Pursued by Arbutus, Moderna, BioNTech & Translate Bio • Woolf, et al “Sense mRNA Therapeutics” US Pat App 60/059371 1997 3) GENOME EDITING BY BASE MOD: • Woolf “Therapeutic repair of mutated nucleic acid sequences” Nature Biotech 1998 • Woolf, et al “To Cleave or not to Cleave” Nature Rev DD 2017 4) GENOME EDITING WITHOUT PROGRAMMABLE NUCLEASES: First to describe modified single-stranded DNA as guide/donor for genome editing. Pursued by ETAGEN & TruCode • “Therapeutic repair of mutated nucleic acid sequences” Woolf, Nature Biotech 1998 • Woolf et al “Compositions and methods for editing nucleic acids” US17/31381 2014 5) STEALTH RNAi (DICER SUBSTRATES): First to commercialize STEALTH RNAi pursued by Sequitur (now Thermo Fisher) and Dicerna • Woolf et al “Double-stranded oligos” US Pat. 10,106,793, 2002 • 4,000 publications used STEALTH RNAi 6) SELF-DELIVERING RNAi 1st oligo delivery conjugate to enter clinical trials (2008). Currently pursued by RXi, UMMC & Advirna. • Woolf, et al “Reduced size self-delivering RNAi compounds” US Patent 10,041,073 2008 • Lapierre et al “Potent and systematic RNAi mediated silencing with single oligo compounds” RNA 2011 7) NEXTGEN GAPMER ANTISENSE Sequitur, Atugen & Oligo Ther., 30M sales. • Woolf et al “3 Component Chimeric Antisense Oligos” US Patent 5849902,1996 • Used to discover the Alzheimer’s beta-secretase Nature 1999 and Science 1999 8) OFF-TARGET EFFECTS. 1st to show off-target antisense by seed sequences. • Woolf, Melton, Jennings “Specificity of antisense oligos in vivo” PNAS 1992 Harvard Medical School

• What industry does Tod Woolf currently work in?

  Tod Woolf currently works in the
  Harvard Medical School

• What is Tod Woolf's area of expertise?

  Tod Woolf specializes in
  Innovative developer of biomedical technologies. Experienced in Academic Technology Transfer, BD, IP management & translation of scientific platforms into products. Communication skills demonstrated by publications, presentations including keynote addresses and team building. Generated >300M in grant, alliance, licenses & equity revenues. Co-developed Therapeutic Editing(1995), MOD mRNA Therapeutics & Vax platform (1997), STEALTH RNAi(2003), Self-Delivering RNAi(2009). Co-founded Sequitur, acquired by Invitrogen and RXi (public, 2008), ETAGEN & participated in formation of more than twenty other startups. Served as CBO at X-Body (acquired by Juno). KEY PATENTS, PUBS & PRODUCTS 1) THERAPEUTIC RNA EDITING: Pursued by ETAGEN, ProQR, Beam & Korro Woolf, et al “Towards the therapeutic editing of mutated RNA sequences” PNAS, 1995 2) mRNA THERAPEUTICS and Vaccines: Early patent application on MOD mRNA for protein replacement & vaccines. Pursued by Arbutus, Moderna, BioNTech & Translate Bio • Woolf, et al “Sense mRNA Therapeutics” US Pat App 60/059371 1997 3) GENOME EDITING BY BASE MOD: • Woolf “Therapeutic repair of mutated nucleic acid sequences” Nature Biotech 1998 • Woolf, et al “To Cleave or not to Cleave” Nature Rev DD 2017 4) GENOME EDITING WITHOUT PROGRAMMABLE NUCLEASES: First to describe modified single-stranded DNA as guide/donor for genome editing. Pursued by ETAGEN & TruCode • “Therapeutic repair of mutated nucleic acid sequences” Woolf, Nature Biotech 1998 • Woolf et al “Compositions and methods for editing nucleic acids” US17/31381 2014 5) STEALTH RNAi (DICER SUBSTRATES): First to commercialize STEALTH RNAi pursued by Sequitur (now Thermo Fisher) and Dicerna • Woolf et al “Double-stranded oligos” US Pat. 10,106,793, 2002 • 4,000 publications used STEALTH RNAi 6) SELF-DELIVERING RNAi 1st oligo delivery conjugate to enter clinical trials (2008). Currently pursued by RXi, UMMC & Advirna. • Woolf, et al “Reduced size self-delivering RNAi compounds” US Patent 10,041,073 2008 • Lapierre et al “Potent and systematic RNAi mediated silencing with single oligo compounds” RNA 2011 7) NEXTGEN GAPMER ANTISENSE Sequitur, Atugen & Oligo Ther., 30M sales. • Woolf et al “3 Component Chimeric Antisense Oligos” US Patent 5849902,1996 • Used to discover the Alzheimer’s beta-secretase Nature 1999 and Science 1999 8) OFF-TARGET EFFECTS. 1st to show off-target antisense by seed sequences. • Woolf, Melton, Jennings “Specificity of antisense oligos in vivo” PNAS 1992

• Which languages does Tod Woolf speak? 

  Tod Woolf speaks the following languages:
  No languages available.

• Which industries has Tod Woolf previously worked in?   

  Tod Woolf has prior experience in the following industries:
  Massachusetts Institute Of Technology , Etagen Pharma , X Body Biosciences , Rxi Pharmaceuticals , Ipifini , Sequitur , Ontogeny , Rpi , California Institute Of Technology

• What is Tod Woolf’s work experience?  

  Tod Woolf has the following professional experience:
  Harvard Medical School , Beth Israel Deaconess Medical Center , Massachusetts Institute Of Technology , Etagen Pharma , Etagen Pharma , X Body Biosciences , Rxi Pharmaceuticals , Ipifini , Sequitur , Ontogeny , Rpi , California Institute Of Technology .

• How can I find Tod Woolf on LinkedIn?  

  You can view Tod Woolf’s
  LinkedIn profile at LinkedIn URL.

• What are Tod Woolf’s work email addresses?  

  Tod Woolf’s work email addresses are
  [email protected] .

• What company does Tod Woolf work for?  

  Tod Woolf works at
  Harvard Medical School